Go Pro
NASDAQ:TENX

Tenax Therapeutics Q2 2026 Earnings Report

Tenax Therapeutics logo
$15.56 -0.42 (-2.63%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$17.05 +1.49 (+9.58%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tenax Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.40
Beat/Miss
N/A
One Year Ago EPS
N/A

Tenax Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenax Therapeutics Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
12:30PM ET

Conference Call Resources

Tenax Therapeutics Earnings Headlines

Tenax Therapeutics (TENX) Gets a Buy from LifeSci Capital
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More Tenax Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email.

About Tenax Therapeutics

Tenax Therapeutics (NASDAQ:TENX) is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials.

Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.

View Tenax Therapeutics Profile